Daily Stock Setups

Alkermes initiates Phase II alcohol dependence study

Posted on: Thu, 19 Nov 2009 09:54:00 EST

Symbols: ALKS

Do you know when to trade ALKS ?

Check for a PowerRating from TradingMarkets

Nov 19, 2009 (Datamonitor via COMTEX) --
ALKS | Quote | Chart | News | PowerRating -- Alkermes has initiated a Phase II clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders.

The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

The Phase II study is designed to assess the safety and efficacy of ALKS 33 in patients with alcohol dependence. In this multi-center, double-blind, placebo-controlled study, up to 440 patients will be randomized to receive daily oral administrations of one of three doses of ALKS 33 or placebo for a total of 12 weeks of treatment.

The Phase II study has an adaptive study design which enables an interim analysis after 40% of the patients are enrolled and on medication for eight weeks of treatment. The efficacy of ALKS 33 will be evaluated based on the percentage of patients who are abstinent from heavy drinking during the eight-week evaluation phase. The pharmacokinetics and safety of ALKS 33 will also be evaluated.

Elliot Ehrich, chief medical officer of Alkermes, said: "The advancement of ALKS 33 in the clinic is an important step as we continue to build our proprietary pipeline, which is based on drugs that we believe have a high likelihood of clinical and commercial success. We expect to use the results from this Phase II study to shape our plans for Phase III clinical development."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

For full details on Alkermes Inc (ALKS) ALKS. Alkermes Inc (ALKS) has Short Term PowerRatings at TradingMarkets. Details on Alkermes Inc (ALKS) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.